![Virginie Miath](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Virginie Miath holds current positions as Non-Executive Director at BioSenic SA starting in 2026, Investment Director at Capital Grand Est SAS, Independent Director at Aton SA since 2023, and Member of the Supervisory Board at Firalis SA.
Aktive Positionen von Virginie Miath
| Unternehmen | Position | Beginn |
|---|---|---|
| ATON | Direktor/Vorstandsmitglied | 20.12.2023 |
| BIOSENIC SA | Direktor/Vorstandsmitglied | 29.01.2026 |
Firalis SA
 Firalis SA BiotechnologyHealth Technology Engages in the discovery and development of biomarker-based diagnostics | Direktor/Vorstandsmitglied | - |
Capital Grand Est SAS
 Capital Grand Est SAS Investment ManagersFinance Capital Grand Est is an active manager which invests in France, Germany and Switzerland. For early-stages financing, the firm typically invests between EUR 250,000 to EUR 3.6 million and for later-stages and growth between EUR 1 million to EUR 5 million. Capital Grand Est invests as a minority or majority stakeholder. | Private Equity Investor | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
34
Beziehungen ersten Grades
4
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Hybrigenics SA
 Hybrigenics SA Pharmaceuticals: MajorHealth Technology Develops therapeutic molecules and genomics | Health Technology |
Firalis SA
Firalis SA BiotechnologyHealth Technology Engages in the discovery and development of biomarker-based diagnostics | Health Technology |
Capital Grand Est SAS
Capital Grand Est SAS Investment ManagersFinance Capital Grand Est is an active manager which invests in France, Germany and Switzerland. For early-stages financing, the firm typically invests between EUR 250,000 to EUR 3.6 million and for later-stages and growth between EUR 1 million to EUR 5 million. Capital Grand Est invests as a minority or majority stakeholder. | Finance |
BioSenic SA
 BioSenic SA BiotechnologyHealth Technology Engages in medical research and develops drugs | Health Technology |
